First-in-Human Single and Multiple Dose of HL-400

Clinical trial NCT06997484 · RECRUITING

Trial details

NCT number: NCT06997484
Sponsor: Highlightll Pharmaceutical (USA) LLC
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Parkinson Disease

Start date: 2025-04-25
Primary completion: 2026-06-30
Enrollment: 86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.